Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine for colorectal neoplasia prevention in Lynch syndrome
NL-OMON44695Phase 2Withdrawn
- Sponsor
- Medical University of Vienna
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Salcrozine in hereditary nonpolyposis colorectal cancer (HNPCC) and colorectal neoplasm (3 arms), sponsored by Medical University of Vienna. Primary endpoint: Occurrence of colonic neoplasms. Planned start May 2017; status: withdrawn.
02
Drugs
Salcrozine
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)colorectal neoplasm
Beyond the preview
Go deeper on NL-OMON44695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44695.